<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219192</url>
  </required_header>
  <id_info>
    <org_study_id>M2ES2010-2</org_study_id>
    <nct_id>NCT01219192</nct_id>
  </id_info>
  <brief_title>Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure</brief_title>
  <official_title>Phase I Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protgen Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protgen Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability and determine the
      recommended dosing for the treatment in patients with advanced pancreatic cancer after
      fist-line Gemcitabine treatment failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and tolerability and determine the recommended dosing for the
      treatment in patients with advanced pancreatic cancer after fist-line Gemcitabine treatment
      failure.We star with the dose M2ES 15mg,then escalate to 30mg 45mg 60mg,to find the
      recommended dose in clinic practise.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MDT</measure>
    <time_frame>3 weeks</time_frame>
    <description>The maximum tolerable dosage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>4 months</time_frame>
    <description>progress free survival</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>M2ES 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M2ES 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M2ES 45mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M2ES 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES</intervention_name>
    <description>M2ES IV D1,8,15,21 every 28 days a cycle</description>
    <arm_group_label>M2ES 15mg</arm_group_label>
    <other_name>M2ES 15mg intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES</intervention_name>
    <description>M2ES IV D1,8,15,21, every 28days a cyce.</description>
    <arm_group_label>M2ES 30mg</arm_group_label>
    <other_name>M2ES 30mg intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES</intervention_name>
    <description>M2ES 45mg IV D1,8,15,22 28days a cycle</description>
    <arm_group_label>M2ES 45mg</arm_group_label>
    <other_name>M2ES 45mg intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES 60mg</intervention_name>
    <description>M2ES 60mg IV D1,8,15,22 every 28days a cycle</description>
    <arm_group_label>M2ES 60mg</arm_group_label>
    <other_name>M2ES 60mg intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically or cytologically confirmed pancreatic adenocarcinoma that was not
             amenable to potentially curative surgery.

          2. All patients must have developed progressive disease (PD) while receiving or within 6
             months after discontinuing palliative gemcitabine-based chemotherapy

          3. Prior radiation therapy was allowed provided that the only sites of measurable disease
             were not located within the radiation port.

          4. 18 years of age or older

          5. Karnofsky performance status (KPS) of 60-100 points

          6. measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
             criteria

          7. Adequate hematologic, renal, and hepatic function was required as deWned by the
             following: WBC ≥3.5×109/L, absolute neutrophil count ≥ 1.5 × 109/L, platelet count
             ≥100 × 109/L, hemoglobin≥9g/dL, total bilirubin ≤2.5 upper limit of normal
             [ULN],AST≤2.5 ULN, or≤5 ULN if there was evidence of liver metastases;alkaline
             phosphatase≤ 2.5 ULN, or≤ 5 ULN if there was evidence of liver Metastases creatinine
             clearance≤50 mL/min,

          8. life expectancy of at least 12 weeks

        Exclusion Criteria:

          1. patients had clinically apparent CNS metastases or carcinomatous meningitis

          2. another active malignancy, or any history of other malignancy within the past 5 years
             except for nonmelanoma skin cancer and carcinoma in situ of the cervix

          3. more than 3 weeks intervals between the last administration of the prior chemotherapy
             regimen and study entry

          4. more than 4 weeks intervals between the last administration of the targeted therapy
             regimen and study entry

          5. major surgery within the prior 6 weeks;

          6. Pregnant or lactating women

          7. tumor involvement of major blood vessels

          8. uncontrolled intercurrent illness

          9. A history of myocardial infarction or stroke within the last 6 months, uncontrolled
             hypertension, unstable angina

         10. clinically significant cardiac disease (eg, congestive heart failure, symptomatic
             coronary artery disease and cardiac arrhythmias not well controlled with medication,
             or myocardial infarction)

         11. urine protein ≥ 500 mg in 24 hours;

         12. evidence of bleeding diathesis or coagulopathy

         13. Patients on therapeutic doses of low-molecular weight heparin

         14. Patients who received thrombolytic agents within the previous month or who required
             full-dose anticoagulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shunchang JIAO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Long CHENG, master</last_name>
    <phone>8610629792458</phone>
    <email>chenglong.bj@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fei WU, master</last_name>
    <phone>8610629792458</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jihui HAO, MD</last_name>
      <phone>862223359929</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Guodong CHANG</name_title>
    <organization>Protgen Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

